Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 32 Multiple Endocrine Neoplasia Type 1 9 Neoplasms 8 Pituitary Neoplasms 7 Carcinoid Tumor 7 Pituitary ACTH Hypersecretion 6 Gastro-enteropancreatic neuroendocrine tumor 6 Differentiated Thyroid Cancer 6 Adrenocortical Carcinoma 6 Thyroid Cancer, Papillary 5 Pituitary Diseases 5 Pheochromocytoma 5 Thyroid Neoplasms 4 Serotonin Syndrome 4 Neuroblastoma 4 Cushing Syndrome 4 Breast Neoplasms 4 Acromegaly 4 ACTH Syndrome, Ectopic 4 Sarcoma 3 Liposarcoma 3 Insulinoma 3 Fibrosarcoma 3 Endometrial Neoplasms 3 Carcinoma, Medullary 3 Adenoma, Islet Cell 3 Adenocarcinoma, Follicular 3 Sarcoma, Synovial 2 Sarcoma, Endometrial Stromal 2 Parkinson Disease 2

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoid Heart Disease × Endocrine × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡